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Aims Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and
reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic





Key inclusion criteria were: New York Heart Association Class II-IV, left ventricular ejection fraction <_ 40%, ele-
vated N-terminal pro-B-type natriuretic peptide level, and SBP >_95 mmHg. The primary outcome was a composite
of worsening heart failure or cardiovascular death. The efficacy and safety of dapagliflozin were examined using
SBP as both a categorical and continuous variable. A total of 1205 patients had a baseline SBP <110 mmHg;
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981 >_ 110 < 120; 1149 >_ 120 < 130; and 1409 >_ 130 mmHg. The placebo-corrected reduction in SBP from baseline
to 2 weeks with dapagliflozin was -2.54 (-3.33 to -1.76) mmHg (P < 0.001), with a smaller between-treatment differ-
ence in patients in the lowest compared to highest SBP category. Patients in the lowest SBP category had a much
higher rate (per 100 person-years) of the primary outcome [20.6, 95% confidence interval (95% CI) 17.6–24.2]
than those in the highest SBP category (13.8, 11.7–16.4). The benefit and safety of dapagliflozin was consistent
across the range of SBP; hazard ratio (95% CI) in each SBP group, lowest to highest: 0.76 (0.60–0.97), 0.76 (0.57–
1.02), 0.81 (0.61–1.08), and 0.67 (0.51–0.87), P interaction = 0.78. Study drug discontinuation did not differ be-
tween dapagliflozin and placebo across the SBP categories examined.
...................................................................................................................................................................................................
Conclusion Dapagliflozin had a small effect on SBP in patients with HFrEF and was superior to placebo in improving outcomes,
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The relationships between blood pressure, outcomes and the effects
of treatment in patients with heart failure and reduced ejection frac-
tion (HFrEF) have been described as paradoxical.1–3 Although most
beneficial treatments for HFrEF reduce systolic blood pressure
(SBP), HFrEF patients with lower SBP have worse outcomes than
those with a higher SBP.1–11 These poor outcomes are often attrib-
uted to low cardiac output and worse haemodynamic status in
patients with low SBP. However, the poor prognosis in patients with
low SBP may also be due to underutilization of effective thera-
pies.12,13 Underuse of these treatments reflects reluctance of physi-
cians to prescribe agents perceived to precipitate or worsen
hypotension and cause problems such as dizziness, syncope, and
renal dysfunction.12,13 Consequently, it is essential that the effects of
new treatments for HFrEF on SBP, and according to SBP, are fully
understood. Sodium-glucose cotransporter-2 (SGLT2) inhibitors are
recommended to lower risk of HF hospitalization in patients with dia-
betes and have been shown to reduce SBP in type 2 diabetic patients
by 3–4 mmHg, similar in size to the reduction obtained with a low
dose of a thiazide diuretic.14,15 We evaluated the effect of SGLT2 in-
hibition on SBP in HFrEF patients, both with and without diabetes,
and the efficacy and safety of dapagliflozin according to baseline SBP,
in the Dapagliflozin and Prevention of Adverse Outcomes in Heart
Failure trial (DAPA-HF).16–18
Methods
Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial
was a randomized, double-blind, placebo-controlled, event-driven, trial in
patients with HFrEF. The efficacy and safety of dapagliflozin 10 mg once
daily, added to standard care, was compared with matching placebo. The
design, baseline characteristics, and primary results of the trial have been
published.16–18 The Ethical Committee of each of the 410 participating
institutions (in 20 countries) approved the protocol, and all patients gave
written informed consent. The corresponding author had full access to
the trial data and takes responsibility for its integrity and the data analysis.
The data underlying this article were provided by AstraZeneca. Data will
be shared on request to the corresponding author with permission of
AstraZeneca.
Study patients
Men and women aged >_18 years with HF were eligible if they were in
New York Heart Association (NYHA) functional Class II to IV, had a left
ventricular ejection fraction (LVEF) <_40%, and were optimally treated
with pharmacological and device therapy for HF. Participants were also
required to have a N-terminal pro-B-type natriuretic peptide (NT-
proBNP) concentration >_600 pg/mL (>_400 pg/mL if hospitalized for HF
within the previous 12 months). Patients with atrial fibrillation or atrial
flutter were required to have a NT-proBNP level >_900 pg/mL, irrespect-
ive of history of HF hospitalization.Key exclusion criteria included: symp-
toms of hypotension or SBP <95 mmHg, estimated glomerular filtration
rate (eGFR) <30 mL/min/1.73m2 (or rapidly declining renal function), and
type 1 diabetes mellitus. A full list of exclusion criteria is provided in the
design paper.16
Study procedures
After the provision of informed consent, Visit 1 started a 14-day screen-
ing period during which the trial inclusion and exclusion criteria were
checked, and baseline information were collected. Visit 2 was the ran-
domization visit, and randomization was stratified based on diagnosis of
type 2 diabetes at screening. After randomization, follow-up visits took
place at 14 and 60 days, and then at 120, 240, 360 days, and every 4
months thereafter. The visit early after randomization (14 days) was
included to check renal function and blood pressure (as well as for symp-
toms of hypotension); this visit also allowed for adjustment of back-
ground diuretic or other non-essential therapies. Dose reduction to 5 mg
of dapagliflozin or matching placebo (or discontinuation of study drug)
was to be considered in case of an acute unexpected decline in eGFR,
volume depletion or hypotension (or to avoid these conditions); how-
ever, dose up-titration (or re-initiation) wasencouraged thereafter in all
cases,where possible.
Study outcomes
The primary outcome was the composite of an episode of worsening
heart failure (HF hospitalization or an urgent visit because of worsening
HF requiring intravenous therapy) or cardiovascular (CV) death, which-
ever occurred first. Secondary endpoints were the occurrence of HF hos-
pitalization or CV death; HF hospitalizations (first and recurrent) and
cardiovascular deaths; change from baseline to 8 months in the total
symptom score of the Kansas City Cardiomyopathy Questionnaire
(KCCQ-TSS);19 the incidence of a composite worsening renal function
outcome, consisting of (a) >_50% sustained decline in eGFR, (b) end-stage
renal disease (defined as sustained eGFR < 15 mL/min/1.73 m2, chronic
dialysis treatment or renal transplantation), or (c) renal death; and death
from any cause. Because of the small number of renal events overall, this
endpoint was not examined in the present analysis of subgroups.
Prespecified safety analyses included any serious adverse event, adverse
events leading to discontinuation of trial treatment, adverse events of
interest (i.e. volume depletion, renal events, major hypoglycaemic events,
bone fractures, diabetic ketoacidosis, and amputation), and any diagnosis
of Fournier’s gangrene, as well as laboratory findings of note.
Statistical analysis
In the present study, patients were divided into four baseline SBP catego-
ries, as in previous studies: (i) <110 mmHg, (ii) >_110 to <120 mmHg, (iii)
>_120 to <130 mmHg, and (iv) >_ 130 mmHg.4–9,20 Systolic blood pressure
was measured at each trial visit (at 14, 60, 120, 240, and 360 days and
every 4 months thereafter). Baseline characteristics were summarized as
means and standard deviations (SDs), median and interquartile ranges, or
percentages. Time-to-event data were evaluated with the use of the
Kaplan–Meier estimates and Cox proportional-hazards models, stratified
according to diabetes status, with a history of HF hospitalization and
treatment group assignment as fixed-effect factors (as prespecified in the
trial statistical analysis plan). In order to investigate a potentially non-
linear relationship of risk across the spectrum of SBP, we also carried out
fractional polynomial analyses of the association between SBP and the
outcomes of interest. We used Cox models to calculate hazard ratios
(HRs), 95% confidence intervals (CIs), and two-sided P-values and used a
semiparametric proportional-rates model to calculate total (including re-
current) events, as previously described.21 We analysed the change in
KCCQ-TSS from baseline to 8 months in surviving patients. Changes in
SBP were assessed by the use of repeated measures mixed model with
treatment, time, and treatment by time interaction as fixed effects, and
time as random effect. Safety analyses were performed in patients who
had undergone randomization and received at least one dose of dapagli-
flozin or placebo (a total of 8 out of 4744 patients were excluded). The
































































































effect of dapagliflozin compared with placebo on each outcome was also
examined across the spectrum of blood pressure, in a Cox regression
model in which SBP was modelled as a continuous variable. A fractional
polynomial was constructed using SBP and entered into the model as an
interaction term with treatment. The results of the interaction were dis-
played graphically using the ‘mfpi’ command in Stata. The polynomial
allows for the possibility of a non-linear effect of treatment by blood pres-
sure to be modelled. The interaction between SBP and treatment effect
on the occurrence of the prespecified safety outcomes was tested in a lo-
gistic regression model with an interaction term between baseline SBP
and treatment. The same analysis was performed for diastolic blood pres-
sure (DBP) and pulse pressure (Supplementary material online,
Appendix). The effect of differences in baseline characteristics was exam-
ined by adjustment of the model in sensitivity analyses (Supplementary
material online, Appendix). Other sensitivity analyses took account of
baseline and post-randomization SBP updated to the time of an event and
time-updated SBP group (Supplementary material online, Appendix), the
effect of treatment according to baseline DBP and the effect of treatment
stratified by diabetes, history of hypertension and heart failure aetiology.
As reported in another recent study,8 we also analysed outcomes in
patients according to achieved SBP in each treatment category, with
patients allocated to two categories according to their achieved SBP at 2
months (‘high’ or ‘low’) or four categories according to their starting and
2-month achieved SBP (high/high, high/low, low/high and, low/low with
‘low’ defined as <_110 mm Hg and ‘high’ >110 mmHg) (Supplementary
material online, Appendix). The correlation between baseline blood pres-
sure and LVEF was studied analysing Pearson’s correlation coefficients
(Supplementary material online, Appendix). The relationship between
change in blood pressure with dapagliflozin at 2 weeks and baseline LVEF
was examined by the use of fractional polynomial analysis
(Supplementary material online, Appendix).
All analyses were conducted using Stata version 15.1 (College Station,
TX, USA). A P-value < 0.05 was considered statistically significant.
Results
The mean and median SBP in the 4744 patients randomized were
121.8 (SD 16.3) and 121.0 (Q1, Q3 109.7–132.0) mmHg, respective-
ly. There were 1205 (25.4%) patients with a baseline SBP
<110 mmHg (mean SBP 102.5 ± 4.9 mmHg), 981 (20.7%) with an SBP
>_110 to <120 mmHg (mean SBP 114.7± 2.9 mmHg), 1149 (24.2%)
with an SBP >_120 to <130 mmHg (mean SBP 124.3± 2.9 mmHg),
1409 (29.7%) with an SBP >_130 mmHg (mean SBP
141.3 ± 11.2 mmHg).
Patient characteristics
The baseline characteristics according to SBP category are shown in
Table 1. Patients with a lower SBP were younger, more often male
and of Asian race. A smaller proportion had a history of hyperten-
sion, diabetes, or coronary heart disease, but they had worse renal
function, lower mean LVEF, and a higher median NT-proBNP level.
The correlation between LVEF and baseline SBP is shown in
Supplementary material online, Figure S1. Patients in the lowest SBP
category were least likely to be treated with an angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker (ARB)
but more frequently received treatment with a diuretic, mineralocor-
ticoid receptor antagonist (MRA), and digoxin. Although overall use
of sacubitril/valsartan was infrequent, patients in the lowest SBP cat-
egory were proportionately most likely to be treated with it. The use
of beta-blocker at baseline was similar across SBP categories. Patients
with lower SBP were more frequently treated with device therapy,
i.e. implantable cardioverter-defibrillator (ICD) or cardiac resynchro-
nization therapy (CRT). Median baseline KCCQ-TSS and NYHA
functional class were similar across SBP categories.
Change in blood pressure
Figure 1 summarizes the difference in change in SBP from baseline to
2 weeks, 2 months, 4 months, and 8 months in each treatment group
and SBP category. These changes are also enumerated in Table 2.
Overall, the mean change in SBP from baseline to 2 weeks was -0.5
(SD 12.0) mmHg in the placebo group and -3.1 (SD 12.3) mmHg in
the dapagliflozin group, resulting in a between-treatment difference
of -2.5 (95% CI -3.3 to -1.8; P < 0.001) mmHg. The corresponding val-
ues at 4 months were: -0.6 (SD 14.0) mmHg in the placebo group
and -2.6 (SD 14.4) mmHg in the dapagliflozin group, difference -1.8
(95% CI -2.7 to -1.0; P < 0.001) mmHg. However, this overall mean
change reflected a divergent pattern of change in patients with a
lower and higher starting SBP. Specifically, SBP increased slightly in
patients with the lowest baseline SBP (e.g. by 3.46 ± 10.21 in the pla-
cebo group and 1.91 ± 11.12 mmHg with dapagliflozin, at 2 weeks)
and decreased in those starting with a higher baseline SBP (e.g.
-4.62 ± 13.01 with placebo and -8.94± 13.26 mmHg with dapagliflo-
zin, at the same time point in patients with SBP >_130 mmHg).
Nevertheless, SBP was still lower in patients assigned to dapagliflozin,
compared with placebo, although the between-treatment difference
was smaller in patients with the lowest baseline SBP (e.g. difference
1.50, 95% CI 0.09–2.92 mmHg at 2 weeks), compared with the high-
est SBP category (4.31, 95% CI 2.71–5.90 mmHg); P for interaction
between baseline SBP category and effect of treatment on SBP was
0.012.
Of participants with a starting SBP >_90 mmHg and with at least
one SBP measurement during the first 8 months (n = 4691), 279
(5.9%) experienced a decrease in SBP below 90 mmHg; 131 (5.6%) in
the placebo group and 148 (6.3%) in the dapagliflozin group
(P = 0.32), without any interaction between SBP category and treat-
ment (P-value for interaction = 0.61). Among participants with a
baseline SBP >_85 mmHg (n = 4697), 132 (2.8%) had a decrease in
SBP to below 85 mmHg, 63 (2.7%) in the placebo group and 69
(2.9%) in the dapagliflozin group (P = 0.60), without any interaction
between SBP category and treatment (P-value for interaction = 0.97).
The effect of dapagliflozin, compared with placebo, on DBP and
pulse pressure is shown in the Supplementary material online, Table
S1 and Figures S2 and S3; the overall pattern of response to dapagliflo-
zin was similar to that seen for SBP. The effect of treatment on SBP
and DBP according to aetiology of heart failure, history of hyperten-
sion, and diabetes status at baseline are also shown in the
Supplementary material online, Table S1. The effect on both SBP and
DBP were small in all subgroups examined. Because lower baseline
blood pressure (and pulse pressure) was associated with lower LVEF,
we also looked at the change in blood pressure (and pulse pressure)
with dapagliflozin according to baseline LVEF. Systolic blood pressure
and pulse pressure tended to increase in patients in the lowest LVEF
category (Supplementary material online, Figure S4). We also exam-
ined change in background therapy and reduction in dose, withhold-
ing and discontinuation of study drug in each treatment group
between baseline and 2 weeks (the blood pressure nadir). Overall,

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































there were no important differences between the two treatment
groups (Supplementary material online, Tables S2–S4).
Association between systolic blood
pressure and clinical outcomes and effect
of dapagliflozin
The unadjusted incidences of the prespecified outcomes, according
to baseline SBP, are shown in Table 3, Figures 2 (primary outcome)
and 3 (individual time-to-first death and hospitalization outcomes).
Fractional polynomial analysis of the association between SBP and
outcomes is shown in Figure 4.
Primary outcome
The incidence of the primary composite outcome, in the placebo
group, was highest in patients with the lowest SBP (<110 mmHg),
next highest in those with SBP >_110–<120 mmHg and plateaued in
the SBP >_120–<130 mmHg and SBP >_130 mmHg groups.
The HR for the effect of dapagliflozin, compared with placebo, on
the primary outcome, was consistent across the spectrum of SBP
(Table 3 and Figure 3A), and the P-value for interaction was 0.78.
Applying the overall relative risk reduction (26%) to the placebo
group event rate in those with SBP < 110 mmHg, gave an absolute
risk reduction of 54 fewer patients experiencing a primary outcome
per 1000 person-years of follow-up. The equivalent absolute risk re-
duction in patients with SBP >_130 mmHg was estimated as 36 fewer
patients per 1000 person-years of follow-up.
Cardiovascular death
The same pattern of relationship between SBP and rate of CV death
was seen in the placebo group and participants in the lowest SBP cat-
egory were at highest risk, as shown in Table 3 and Figure 3B. The ef-
fect of dapagliflozin, compared with placebo, was consistent across
the spectrum of SBP (P-value for interaction = 0.22).
Worsening heart failure events
There was a steeper gradient in worsening HF events across SBP
categories than seen for CV death (Table 3). However, the effect
of dapagliflozin, compared with placebo, remained consistent
across SBP categories, including in patients with SBP <110 mmHg
(Table 3 and Figure 3C). Applying the overall relative risk reduction
(30%) to the placebo group event rate in participants with SBP
<110 mmHg, gave an absolute risk reduction of 32 per 1000
person-years of follow-up. The equivalent absolute risk reduction
in patients with SBP >_130 mmHg was 21 per 1000 person-years
of follow-up.
All-cause mortality
The relationship between SBP and death from any cause was like the
pattern seen for CV death. The effect of dapagliflozin compared with
placebo was consistent across the spectrum of SBP (Table 3 and
Figure 3D; P-value for interaction 0.37). Applying the overall relative
risk reduction (17%) to placebo group event rate in those with SBP
<110 mmHg, gave an absolute risk reduction of 25 fewer deaths per
1000 person-years of follow-up. The equivalent absolute risk reduc-
tion in patients with SBP >_130 mmHg was estimated as 14 fewer
deaths per 1000 person-years.
Composite of recurrent heart failure hospitalization and
cardiovascular death
As for the other endpoints, we observed a consistent effect of dapa-
gliflozin on the occurrence of first and recurrent HF hospitalization
and CV death across SBP categories (Table 3) (P-value for interaction
=0.99).
Effect of dapagliflozin compared to
placebo examining systolic blood
pressure as a continuous variable
Figure 4 provides an alternative illustration of the effects of dapagliflo-
zin compared with placebo, for the four outcomes described above,
using fractional polynomial analysis. Each panel shows a continuous
HR (with 95% CI) for dapagliflozin, compared with placebo, across
the spectrum of SBP (SBP shown as a continuous variable on the X-
axis). As in the categorical analysis, the effect of dapagliflozin, com-
pared with placebo, was consistent across the entire spectrum of
SBP, with non-significant P-values for interaction for all endpoints.
Similar findings were also observed after adjusting for differences in
baseline characteristics (Supplementary material online, Table S5 and
Figure S5).
The effect of dapagliflozin was also consistent across the range of
DBP and pulse pressure included in the trial (Supplementary material
online, Figures S6 and S7). These findings were also true for both SBP
and DBP, irrespective of aetiology of heart failure (Supplementary
material online, Figure S8a,b) or history of hypertension
(Supplementary material online, Figure S9a,b).
Sensitivity analyses, time-updated systol-
ic blood pressure analysis and achieved
systolic blood pressure analysis
We also studied the effect of dapagliflozin in different Cox regression
models taking account of, respectively: baseline SBP, baseline SBP cat-
egory, baseline and post-randomization SBP updated to the time of
an event, and time-updated SBP category (Supplementary material
online, Figures S10–S13). These model adjustments did not change
Figure 1 Placebo-corrected change in systolic blood pressure
with dapagliflozin from baseline to 2 weeks, 2 months, 4 months,
and 8 months. The figure shows effect of dapagliflozin on SBP during
the first 8 months of treatment for the overall population and for
each baseline SBP groups.




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































our finding of a consistent benefit of dapagliflozin, irrespective of
baseline SBP.
Supplementary material online, Figure S12 shows Kaplan–Meier
curves for the achieved SBP at 2 months analysis (high or low cat-
egory) and Supplementary material online, Figure S13 the high/high,
high/low, low/high, and low/low analysis of achieved SBP at 2 months
(‘low’ defined as <_110 mm Hg and ‘high’ >110 mmHg). While a low
2-month SBP was associated with worse outcomes in placebo-
treated patients, this was not the case in those treated with dapagli-
flozin. In the 4-category analysis taking account of both baseline and
2-month SBP (high/high, high/low, low/high and low/low analysis),
placebo-treated patients with persistently low SBP and those that
decreased to low SBP after 2 months had worse outcomes than the
equivalent dapagliflozin-treated patients (Supplementary material on-
line, Figure S13).
Change in Kansas City Cardiomyopathy
Questionnaire at 8 months
As shown in Table 3, patients treated with dapagliflozin, overall,
had a greater increase (improvement) in the KCCQ-TSS be-
tween baseline and 8 months and this benefit of dapagliflozin
was consistent across SBP categories (P-value for interaction =
0.06). The proportion of patients with an improvement of
KCCQ-TSS of >_5 points was larger in patients treated with
dapagliflozin, compared to patients treated with placebo.
Conversely, the proportion of patients with a decrease in
KCCQ-TSS of >_5 points (i.e. a clinically meaningful deterior-
ation) was smaller in those treated with dapagliflozin. The bene-
fit of dapagliflozin over placebo in preventing deterioration of
KCCQ-TSS, was consistent across SBP categories (P-value for
interaction = 0.40). The proportion of participants reporting
a >_ 5-point improvement in KCCQ-TSS varied inconsistently
across SBP categories, with an interaction between baseline SBP
and treatment with dapagliflozin of borderline significance (P-
value for interaction = 0.04).
Prespecified safety assessments
The proportion of patients stopping study drug for any reason in the
placebo group was highest in patients with the lowest SBP (Table 4).
However, the rate of discontinuation was similar between dapagliflo-
zin and placebo across all SBP categories (P-value for interaction
Figure 2 Cumulative Incidence of primary outcome in each systolic blood pressure category. The figure shows Kaplan–Meier event curves for pla-
cebo (red dashed line) and dapagliflozin (blue line) in each baseline SBP group.


































..=0.34). A similar pattern was seen for treatment discontinuation due
to adverse events.
Adverse events related to volume depletion were reported in
12.3% of the placebo group with SBP <110 mmHg and in 13.3% in
the dapagliflozin group. Serious adverse events related to volume de-
pletion occurred, overall, in 29 patients (1.2%) in the dapagliflozin
group and 40 patients (1.7%) in the placebo group, with no inter-
action between SBP category and treatment (P for interaction =
0.26).
Renal adverse events were generally less frequent in patients
treated with dapagliflozin than placebo for each SBP category, except
for patients with SBP >_130 mmHg who appeared to experience
more renal adverse events with dapagliflozin (P-value for inter-
action = 0.015). However, serious renal events were less common
with dapagliflozin, compared to placebo, across each SBP category
(P-value for interaction = 0.23). The mean change in serum creatinine
with dapagliflozin at 8 months was minimal across each SBP category
(P-value for interaction =0.77) and relatively few patients in any SBP
group (and either treatment group) experienced a doubling of serum
creatinine.
Discussion
We found that lower SBP was associated with worse outcomes in
HFrEF, although risk increased steeply only in patients with SBP
<110 mmHg, who constituted 25% of participants in DAPA-HF, in
keeping with the proportion reported in recent registries.1–9,12,20,22
The benefit of dapagliflozin on death and hospitalization for heart fail-
ure was consistent across the range of SBP at baseline, whether SBP
was analysed as a categorical or continuous variable (and the latter
was also true for DBP). This remained true after adjustment for other
baseline differences between patients in the various SBP categories
and adjustment for SBP after randomization. Remarkably, compared
Figure 3 Hazard ratio for dapagliflozin, compared with placebo, for each outcome of interest, according to baseline systolic blood pressure cat-
egory. The figures show unadjusted hazard ratios for the primary outcome (A), cardiovascular death (B), heart failure hospitalization/urgent visit (C),
and all-cause death (D).










































with placebo, dapagliflozin was well tolerated in the lowest SBP
group, despite reducing SBP slightly and even though patients with
SBP <110 mmHg also had the worst renal function. Indeed, the
rate of discontinuation of dapagliflozin was relatively low in partic-
ipants with SBP <110 mmHg and not more than the rate of dis-
continuation of placebo (although the rate of discontinuation of
both study treatments was slightly greater than in participants
with a higher baseline SBP). Notably, patients in the lowest SBP
group experienced an increase in SBP after randomization, while
patients in the highest SBP group experienced a decrease. In part
at least, this likely reflects the statistical phenomenon of ‘regression
to the mean’, although SBP might also increase in some patients as
a result of improvement in cardiac function with treatment.
Perhaps the most important finding of this study is that not
only was dapagliflozin safe and well tolerated, even in patients
with a baseline SBP <110 mmHg, but the absolute benefit of the
drug was particularly large in those with the lowest SBP
<110 mmHg. Indeed, because patients in the lowest SBP category
had a higher rate of events, dapagliflozin-treated patients experi-
enced 54 fewer primary outcomes per 1000 person-years of
follow-up in this lowest SBP category compared with 36 fewer
patients in the highest SBP category. Interestingly, patients in the
lowest SBP group were well treated with conventional therapy,
with only a slightly lower rate of use of renin–angiotensin system
blockers (92% vs. 96% in the highest SBP category), a similar fre-
quency of use of a beta-blocker and greater use of diuretic, di-
goxin, MRA, and sacubitril/valsartan, as well as cardiac
resynchronization therapy and ICD. The greater use of the latter
pharmacological and device therapies is likely to reflect more
advanced disease in patients with a low SBP, as evidenced by their
lower LVEF, higher NT-proBNP level and worse renal function. It
is, therefore, important to emphasize that dapagliflozin has bene-
fits over and above those of conventional disease-modifying thera-
pies, especially in this highest risk group of patients. These findings
should allay any concerns about using dapagliflozin in patients with
low SBP.
It is also of interest to compare the effect of dapagliflozin on SBP in
patients with HFrEF to its effect on SBP in patients without HFrEF. In
a meta-analysis of 13 studies in individuals with type 2 diabetes, the
placebo-corrected change in SBP from baseline to 6 months with
dapagliflozin 10 mg was -3.6 (95% CI -4.9 to -2.4) mmHg, -2.6 (95%
CI -3.4 to -1.8) mmHg, and -2.5 (95% CI -3.9 to -1.1) mmHg in
Figure 4 Hazard ratio for dapagliflozin, compared with placebo, for each clinical outcome, according to baseline systolic blood pressure modelled
as a continuous variable. The figures show a continuous hazard ratio (green line) for treatment with dapagliflozin, compared to placebo, according to
baseline systolic blood pressure. The interrupted red line shows a hazard ratio of 1 (i.e. unity, representing no treatment effect) and the grey shaded
area the 95% confidence interval around the hazard ratio.












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.patients with SBP >140 mm Hg, <_140 mmHg, and <_120 mmHg, re-
spectively.23 In our patients with SBP >_130 mmHg, the change at
2 weeks was -4.31 (95% CI -5.90 to -2.71) and -1.49 (95% CI -3.21 to
0.24) mmHg at 8 months. In participants with SBP <110 mmHg, there
was a non-significant change of -1.50 (95% CI -2.92 to -0.09) mmHg
at 2 weeks and -0.68 (95% CI -2.27 to 0.91) mmHg at 8 months. This
finding of a smaller hypotensive effect of a blood pressure-lowering
drug in HFrEF, compared to patients without HFrEF, is consistent
with what has been found with beta-blockers, ARBs, and MRAs and
remains unexplained.4–9 One hypothesis is that effective therapy may
improve cardiac output in patients with HFrEF, offsetting any direct,
treatment-induced, reduction in SBP.8 It is also notable that, in our
supplementary analyses, a decrease in SBP in the placebo group was
associated with worse outcomes, whereas that was not the case in
the dapagliflozin group, emphasizing the prognostic difference be-
tween a spontaneous decline in SBP and one caused by the addition
of a disease-modifying treatment.4–9
In view of the potential withholding of life-saving therapy due to
concern about hypotension, it is also important to highlight that only
a small proportion of patients experienced a decline in SBP to below
90 mmHg and this proportion was similar in each treatment group
(6.3% with dapagliflozin and 5.6% with placebo); the equivalent pro-
portion with a SBP decreasing to <85 mmHg was even smaller and
balanced between treatment groups (2.9% and 2.7%, respectively).1–
3,12,22 Likewise, no adverse event of interest was meaningfully more
frequent with dapagliflozin, compared to placebo, in patients with
SBP <110 mmHg.
Our analyses have some limitations. They are post hoc as no
subgroup analysis was prespecified for the effect of treatment
according to SBP (although analysis of change in SBP was prespe-
cified). The SBP categories chosen were arbitrary (although the
same as those used in prior studies).4–9,20 Our results are not ap-
plicable to patients with SBP <95 mmHg or presenting with symp-
toms of hypotension, as they were excluded from DAPA-HF.16
The other exclusion criteria (e.g. reduced eGFR) also limit the
generalizability of our results.
In conclusion, dapagliflozin reduced the risk of death and worsen-
ing heart failure, and improved symptoms, across the broad range of
baseline SBP studied in DAPA-HF. The effect of dapagliflozin on SBP
was small in patients with HFrEF (Take home figure). There was no
Take home figure In patients with heart failure and impaired left ventricular (LV) systolic function, reduced cardiac output results in low systol-
ic blood pressure (SBP) and heightened risk of adverse clinical outcomes. Hypotension also leads to withholding and intolerance of treatments that
lower blood pressure further, denying patients life-saving therapy. We found that dapagliflozin resulted in a small reduction in systolic blood pressure
andwas beneficial across the range of pressures measured at baseline in patients included in the Dapagliflozin and Prevention of Adverse Outcomes
in Heart Failure trial (DAPA-HF).
































































































significant imbalance in adverse events or treatment discontinuation
between dapagliflozin and placebo, even in individuals with SBP
<110 mmHg.
Supplementary material
Supplementary material is available at European Heart Journal online.
Funding
AstraZeneca; British Heart Foundation Centre of Research Excellence
(RE/18/6/34217 to J.J.V.McM.).
Conflict of interest: K.F.D. reports receiving grant support from
Novartis. P.S.J. reports his employer the University of Glasgow being paid
by AstraZeneca for his time working on the DAPA-HF and DELIVER tri-
als and by Novartis for working on the PARADIGM-HF and PARAGON-
HF trials; receiving consulting fees, advisory board fees, and lecture fees
from Novartis; advisory board fees from Cytokinetics; and grant support
from Boehringer Ingelheim. S.E.I. receiving advisory fees from
AstraZeneca and Zafgen; lecture fees, consulting fees, fees for serving as a
clinical trial publications committee member, reimbursement for medical
writing, and travel support from Boehringer Ingelheim; fees for serving on
a steering committee and travel support from Sanofi/Lexicon; lecture
fees, consulting fees, and travel support from Merck; and advisory fees
and travel support from VTV Therapeutics and Abbott/Alere. L.K. receiv-
ing lecture fees from Novartis and Bristol-Myers Squibb. M.N.K. receiving
grant support, honoraria, and research support from AstraZeneca; grant
support and honoraria from Boehringer Ingelheim; and honoraria from
Sanofi, Amgen, NovoNordisk, Merck (Diabetes), Eisai, Janssen, Bayer,
GlaxoSmithKline, Glytec, Intarcia, Novartis, Applied Therapeutics,
Amarin, and Eli Lilly. P.P. receiving consulting fees, fees for serving on a
speakers bureau, and participating in clinical trials for Boehringer
Ingelheim; lecture fees from Pfizer; participation in clinical trials for
Amgen, grant support, paid to his institution; fees for serving on a speak-
ers bureau, consulting fees, and participation in clinical trials for Vifor
Pharma; fees for serving on a speakers bureau and consulting fees from
Servier; fees for serving on a speakers bureau, consulting fees, and partici-
pation in clinical trials for Bayer; fees for serving on a speakers bureau,
consulting fees, and participation in clinical trials for BMS; fees for serving
on a speakers bureau and consulting fees from Respicardia; fees for serv-
ing on a speakers bureau from Berlin-Chemie; fees for serving on a speak-
ers bureau, consulting fees, and participation in clinical trials for Cibiem;
fees for serving on a speakers bureau, consulting fees, and participation in
clinical trials for Novartis; and fees for serving on a speakers bureau, con-
sulting fees, and participation in clinical trials for RenalGuard. D.L.D.
receiving consulting fees from Frontier Science, Actelion, BMS,
Medtronic, Boston Scientific, GSK, and Merck; and consulting fees and
being owner of D L DeMets Consulting. M.S.S. receiving grant support,
paid to Brigham and Women’s Hospital, and consulting fees from Amgen,
AstraZeneca, Intarcia, Janssen Research and Development, The
Medicines Company, MedImmune, Merck, and Novartis; consulting fees
from Anthos Therapeutics, Bristol-Myers Squibb, CVS Caremark,
DalCor, Dynamix, Esperion, IFM Therapeutics, and Ionis, grant support,
paid to Brigham and Woman’s Hospital, from Bayer, Daiichi Sankyo, Eisai,
GlaxoSmithKline, Pfizer, Poxel, Quark Pharmaceuticals, and Takeda; and
serving as a member of the TIMI Study Group, which receives grant sup-
port, paid to Brigham and Women’s Hospital, from Abbott, Aralez,
Roche, and Zora Biosciences. O.B. and M.S. being employed by
AstraZeneca. A.M.L. being employed and holding shares in AstraZeneca.
M.D. receiving personal fees from AstraZeneca during the conduct of the
study. J.G.H. receiving grant support, consulting fees, and lecture fees
from AstraZeneca, Boehringer Ingelheim, Novartis, and Servier; consult-
ing fees and lecture fees from Novo Nordisk; consulting fees from
Janssen, and grant support, consulting fees, lecture fees, and provision of
drugs from Pfizer. T.K. receiving fees for serving as national coordinator
of a trial from Novartis and AstraZeneca. C.E.A.L. receiving lecture fees
and advisory board fees from AstraZeneca, lecture fees from Novartis,
and advisory board fees from Pfizer. S.V. receiving grant support, lecture
fees, and advisory board fees from AstraZeneca, Boehringer Ingelheim,
Bayer, Janssen, and Merck; lecture fees from Sun Pharmaceuticals and
EOCI Pharmacomm, grant support and advisory board fees from Amgen;
and lecture fees and advisory board fees from Sanofi and Eli Lilly. S.D.S.
receiving grant support and consulting fees from Alnylam, Amgen,
AstraZeneca, BMS, Gilead, GSK, MyoKardia, Novartis, Theracos, Bayer,
and Cytokinetics; grant support from Bellerophon, Celladon, Ionis, Lone
Star Heart, Mesoblast, Sanofi Pasteur, and Eidos; consulting fees from
Akros, Corvia, Ironwood, Merck, Roche, Takeda, Quantum Genomics,
AoBiome, Caridac Dimensions, Tenaya, and Daiichi Sankyo; and fees for
serving on a DSMB from Janssen. S.E.I reports personal fees and nonfinan-
cial support from AstraZeneca, Boehringer Ingelheim, Sanofi/Lexicon,
Merck, VTV Therapeutics, and Abbott/Alere, as well as personal fees
from AstraZeneca and Zafgen. L.K reports other support from
AstraZeneca and personal fees from Novartis and Bristol-Myers Squibb
as a speaker. F.A.M reports personal fees from AstraZeneca. S.D.S
reports grants from AstraZeneca, Bellerophon, Celladon, Ionis, Lone Star
Heart, Mesoblast, National Institutes of Health/National Heart, Lung, and
Blood Institute, Sanofi Pasteur, and Eidos; grants and personal fees from
Alnylam, Amgen, AstraZeneca, BMS, Gilead, GSK, MyoKardia, Novartis,
Theracos, Bayer, and Cytokinetics; and personal fees from Akros, Corvia,
Ironwood, Merck, Roche, Takeda, Quantum Genomics, AoBiome,
Janssen, Cardiac Dimensions, Tenaya, and Daichi-Sankyo. C.C. reports
personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-
Sankyo, MSD, Novartis, Pfizer, and Sanofi. M.B. receiving lecture fees
from Amgen, Bayer, Servier, Medtronic, Boehringer Ingelheim, Vifor
Pharma, and Bristol-Myers Squibb, grant support and lecture fees from
AstraZeneca, and grant support from Deutsche Forschungsgemeinschaft.
I.S.A. receiving fees for serving as United States national leader of a trial
from AstraZeneca, fees for serving on a steering committee from ARCA
Biopharma, Amgen, LivaNova, and Novartis, fees for serving on an
Endpoint committee from Boehringer Ingelheim, fees for serving as chair
of a data and safety monitoring board from Boston Scientific, and advisory
board fees from Zensun. R.A.B. grant support (paid to University Medical
Center Groningen [UMCG]) and lecture fees from Novartis; grant sup-
port (paid to UMCG) from NovoNordisk, receiving grant support (paid
to UMCG), consulting fees, and lecture fees from AstraZeneca, grant
support (paid to UMCG) from Bristol-Myers Squibb, grant support (paid
to UMCG) and consulting fees from Abbott, grant support (paid to
UMCG) and lecture fees from Roche, and consulting fees from
MandalMed and being a minority shareholder in scPharmaceuticals. J.G.H,
receiving grant support, consulting fees, and lecture fees from
AstraZeneca, Boehringer Ingelheim, Novartis, and Servier, consulting fees
and lecture fees from Novo Nordisk, consulting fees from Janssen, and
grant support, consulting fees, lecture fees, and provision of drugs from
Pfizer. M.K. receiving grant support and lecture fees from Astellas
Pharma, Sanofi, Pfizer, Ono Pharmaceutical, Novartis, and Mitsubishi
Tanabe Pharma, lecture fees from Daiichi Sankyo, Bayer, Boehringer
Ingelheim, Kowa Pharmaceutical, Sawai Pharmaceutical, MSD, Shionogi,
Kureha, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, and Toa
Eiyo, and manuscript fees from Japan Medical Data Center. C.EA.L receiv-
ing lecture fees and advisory board fees from AstraZeneca, lecture fees
from Novartis, and advisory board fees from Pfizer. J.J.V.M. receiving fees
(all fees listed paid to Glasgow University) for serving on a steering com-
mittee from Bayer, fees for serving on a steering committee, fees for
































































































serving on an endpoint committee, and travel support from Cardiorentis,
fees for serving on a steering committee and travel support from Amgen,
fees for serving on a steering committee and travel support from Oxford
University/Bayer, fees for serving as principal investigator of a trial and
travel support from Theracos, fees for serving on a steering committee
and travel support from AbbVie, fees for serving on a steering committee
from DalCor, fees for serving on a data safety monitoring committee
from Pfizer, fees for serving on a data safety monitoring committee from
Merck, fees for serving on an executive committee, fees for serving as co-
principal investigator of a trial, fees for serving on a steering committee,
fees for serving on an executive committee, travel support, and advisory
board fees from Novartis, fees for serving as co-principal investigator for
a trial, fees for serving on a steering committee, and travel support from
GlaxoSmithKline, fees for serving on a steering committee from Bristol-
Myers Squibb, fees for serving on a steering committee, fees for serving
on an endpoint adjudication committee, and travel support from Vifor-
Fresenius. No other conflict of interest relevant to this article was
reported.
References
1. Ventura HO, Messerli FH, Lavie CJ. Observations on the blood pressure paradox
in heart failure. Eur J Heart Fail 2017;19:843–845.
2. Raphael CE, Whinnett ZI, Davies JE, Fontana M, Ferenczi EA, Manisty CH, Mayet
J, Francis DP. Quantifying the paradoxical effect of higher systolic blood pressure
on mortality in chronic heart failure. Heart 2008;95:56–62.
3. Pfeffer MA. Blood pressure in heart failure. A love-hate relationship. J Am Coll
Cardiol 2007;49:40–42.
4. Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB,
Coats AJS, Castaigne A, Scherhag A, Holcslaw TL, Packer M. Influence of pre-
treatment systolic blood pressure on the effect of carvedilol in patients with se-
vere chronic heart failure: the Carvedilol Prospective Randomized Cumulative
Survival (COPERNICUS) study. J Am Coll Cardiol 2004;43:1423–1429.
5. Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN. Effect of
baseline and changes in systolic blood pressure over time on the effectiveness of
valsartan in the Valsartan Heart Failure Trial. Circ Heart Fail 2008;1:34–42.
6. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT,
Adams KF, Olukotun AY, Worcel M, Cohn JN. Influence of blood pressure on
the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydrala-
zine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007;49:32–39.
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SD; on behalf of the DAPA-HF Committees and Investigators. The Dapagliflozin
And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline
characteristics. Eur J Heart Fail 2019;21:1402–1411.
18. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA,
Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra
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PS, Bengtsson O, Sjöstrand M, Langkilde AM. Dapagliflozin in patients with heart
failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008.
19. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation
of the Kansas City cardiomyopathy questionnaire: a new health status measure
for heart failure. J Am Coll Cardiol 2000; 35:1245–1255.
20. Komajda M, Bohm M, Borer JS, Ford I, Robertson M, Manolis AJ, Tavazzi L,
Swedberg K; on behalf of the SHIFT Investigators. Efficacy and safety of ivabra-
dine in patients with chronic systolic heart failure according to blood pressure
level in SHIFT. Eur J Heart Fail 2014;16:810–816.
21. Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP,
Packer M, Rouleau JL, Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-
Velten G, McMurray J. Effect of sacubitril/valsartan on recurrent events in the
Prospective comparison of ARNI with ACEI to Determine Impact on Global
Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail
2018;20:760–768.
22. Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL,
McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez
AF, Fonarow GC. Medical therapy for heart failure with reduced ejection frac-
tion: the CHAMP-HF registry. J Am Coll Cardiol 2018;72:351–366.
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